Pressure
BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly
enabling, pressure-based instruments, consumables, services, and platform
solutions to the worldwide life sciences industry, today announced financial
results for the third quarter ended September 30, 2019, provided a business
update and offered limited guidance for FY2020. “We have consistently
highlighted the importance of the “razor/razor blade” business model. In
the 3rd quarter, consumable sales for our pressure cycling technology (“PCT”)
platform exceeded $100,000/quarter for the first time, increasing by 158% over
the same quarter last year,” PBI President and CEO Richard T. Schumacher said
in the news release. “A significant portion of this accelerating growth came
from scientists working in cancer research centers worldwide. These researchers
use PBI’s PCT platform in studies focused on improving cancer diagnostics,
prognostics, therapeutics, and prevention. For example, on October 1st we
announced that the research group led by nationally acclaimed cancer researcher
Dr. Tom Conrads (Sr. Director of Women’s Health Research at the Inova Women’s
Hospital, Fairfax, VA) had developed a novel workflow that could enable the
identification of biomarkers associated with women’s cancers and possibly
result in significant improvements in the clinical management of gynecologic
cancer. Dr. Conrads’ comments highlighted that PBI’s PCT platform was an
essential part of their workflow.”
To view the full press release, visit http://ibn.fm/z2enF
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold,
Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract
services sector, and (2) the use of its recently-patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create
stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and
to (ii) prepare higher quality, homogenized, extended shelf-life or room
temperature stable low-acid liquid foods that cannot be effectively preserved
using existing non-thermal technologies. For more information, visit the
company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.htm
